The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

December 1, 2008 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Systemic lupus erythematosus, often called SLE or lupus, is a chronic inflammatory disease that can affect the skin, joints, kidneys, lungs, nervous system, and other organs of the body. It is sometimes labeled the “great imitator” because its wide variety of symptoms can often be confused with other disorders. Usually, patients with SLE experience skin rashes and arthritis as well as fatigue and fever, and the disease can be fatal. However, improvements in therapy have significantly increased these patients’ quality of life and their life expectancy.

You Might Also Like
  • Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
  • Tabalumab Modestly Effective in Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report
Explore This Issue
December 2008
Also By This Author
  • Coding Corner Question

SLE typically develops in people in their 20s and 30s, and it develops 10 times more often in women than in men. It is more common in certain ethnic groups, particularly among African Americans and Asians, who also tend to be more severely affected.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The immune system normally protects the body by producing antibodies that attack foreign germs and cancers. With SLE, the immune system misfires. Instead of producing protective antibodies, the autoimmune disorder begins manufacturing “auto-antibodies” that attack the patient’s own tissues. This leads to inflammation and blood vessel abnormalities (vasculitis). These antibodies then end up in the immune system of cells in organs where they cause tissue damage. Why this inflammatory reaction begins is not known, but according to patient–fact sheet writers Ellen Ginzler, MD, and Jean Tayar, MD, “It is probably the result of a combination of inherited tendencies and environmental factors, such as viruses, the ultraviolet rays in sunlight, Silica dust, and allergies to medications.”

Diagnosis of SLE is difficult due to the gradual development of the symptoms. Suspected cases must be confirmed by a series of blood tests. More specific tests, such as the anti–double-strand DNA and anti-Smith antibodies, confirm the diagnosis of SLE. Levels of certain complement proteins (a part of the immune system) in the blood are also measured to help diagnose and track the disease. Physicians frequently use the 1997 update of the 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus to aid them in considering whether a patient with symptoms may have SLE. “Although this table was originally designed for clinical research studies, it can be helpful when considering an individual patient as well,” say Drs. Ginzler and Tayar.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There is no cure for SLE, and its management can be a challenge. However, in the past several years, treatment has improved considerably, and recent medical developments have proven effective. Treatment decisions are based on symptoms and the severity of those symptoms. Patients with muscle or joint pain, fatigue, skin abnormalities (such as rashes), and other responses that are not life threatening can be treated conservatively. Those with serious and life-threatening problems—such as kidney inflammation, lung or heart involvement, and central nervous system symptoms—need more aggressive therapy. Treatment depends on an individual assessment of risks and benefits. Most immunosuppressive medications, for instance, may cause significant side effects, such as increased risk of infections, nausea, vomiting, hair loss, diarrhea, high blood pressure, and osteoporosis. Rheumatologists may reduce or discontinue a medication after the disease goes into remission for a period of time.

Even when it is not active, SLE may cause problems later, such as kidney disease, which can progress to renal failure and can require dialysis. This can be prevented by early and aggressive treatment at the first signs of kidney disease. Another problem is accelerated atherosclerosis, which increases the risk of heart attacks and other cardiovascular events. It is crucial that SLE patients reduce other risk factors such as smoking, high blood pressure, and high cholesterol to reduce their risk for these complications. Most people with SLE can live normal lives, but this disorder must be carefully monitored and treatment should be adjusted as necessary to prevent serious complications.

Download the complete SLE fact sheet and other patient-education materials at www.rheumatology.org by following the links to patient education from the Practice Support Menu.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Multi-Page

Filed Under: Conditions, From the College, SLE (Lupus) Tagged With: Diagnostic Criteria, Lupus, Patient Fact Sheet, SLE, systemic lupus erythematousIssue: December 2008

You Might Also Like:
  • Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
  • Tabalumab Modestly Effective in Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report
  • Accelerating Medicines Partnership Targets Therapies for Rheumatoid Arthritis, Systemic Lupus Erythematosus

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.